[BIO USA] 카지노 바카라 Biologics transitions to CRDMO after 7 years… ‘R’ standing for ‘organoids’

[by Ji, Yong Jun] 카지노 바카라 Biologics has entered a new phase in its evolution, shifting from a bio-manufacturing company to a technology-driven enterprise. The company is pursuing a transformation from a contract development and manufacturing organization (CDMO) to a contract research, development, and manufacturing organization (CRDMO) by incorporating the ‘R (Research)’ component into its service portfolio.

카지노 바카라 Biologics, which began as a contract manufacturing organization (CMO) for biopharmaceuticals in 2011, expanded into contract development (CDO) in 2018, seven years later. In 2025, another seven years on, the company will further expand its scope to include contract research (CRO). The forefront of this expansion into the ‘R’esearch domain is marked by its introduction of ‘organoids’ as a key strategic platform.

On June 17 (local time), Lee Sang-myung, Vice President of Business Strategy at 카지노 바카라 Biologics, held a press conference at ‘BIO USA 2025’ in Boston, USA, where he expressed, “With the launch of the ‘카지노 바카라 Organoids’ service, we will expand our business portfolio from manufacturing to technology.”

The term ‘organoid’ is derived from the combination of ‘organ,’ referring to a human organ, and the suffix ‘oid,’ meaning resembling or similar. It describes a three-dimensional ‘mini organ model’ cultured by aggregating stem cells or tissue-derived cells. Organoids exhibit a high degree of patient similarity of up to 85%, offering a significant advantage in accurately reflecting human disease biology compared to traditional animal testing models.

In academic research, approximately 40% of scientists have reported using organoids in their studies. Reflecting this trend, the U.S. Food and Drug Administration (FDA) has announced plans to gradually phase out animal testing in favor of alternative methods, including the use of organoids and artificial intelligence (AI).

“Animal models have limited correlation with actual patient responses and are therefore used only as supplementary data,” Lee stated. “Organoids, with their three-dimensional structure, enable more precise observation of patient-specific reactions to drug administration.”

The 카지노 바카라 Organoids Service is designed to meet customer demands with a strong emphasis on quality. The service aims to deliver high quality organoid production aligned with GxP (Good x Practice) standards encompassing manufacturing, testing, and clinical procedures, rapid, customized organoid solutions, reliable data generation, and clinically relevant insights based on data analysis. Lee further noted that an ‘organoid lab’ has been established within the antibody-drug conjugate (ADC) dedicated production facility located in Songdo, Incheon City.

카지노 바카라 Biologics has set its initial focus on developing cancer model organoids. The company has secured organoids for various cancer types and has validated the high quality of its service, demonstrating a drug response consistency rate exceeding 85% when compared with actual clinical data, particularly in pancreatic cancer-derived organoids.

The competitiveness of the Organoids Service has been further enhanced through a partnership with 카지노 바카라 Medical Center, one of Korea’s top five university hospitals. Ranked third globally in cancer treatment by Newsweek in 2025, 카지노 바카라 Medical Center brings substantial clinical expertise in the field of cancer treatment and research, with over 19 billion clinical data points and treatment experience from 4.5 million patients as of May 2024. This collaboration will provide valuable clinical insights into treatment targets and patient responses.

With the launch of the 카지노 바카라 Organoids Service, 카지노 바카라 Biologics intends to expand its business portfolio beyond manufacturing into the field of advanced technology. Since its founding as a CMO in 2011, the company has been steadily broadening its scope, entering the CDO sector in 2018 and further advancing into CRO this year.

“By entering the CRO business, we aim to deliver a customer-centered, ‘end-to-end’ CRDMO service that enhances our understanding of pharmaceutical mechanisms of action and supports novel drug development,” Lee said. “By initiating collaboration from the early stages of a client’s new drug candidate discovery, we anticipate generating an ‘early lock-in’ effect (a strategy to foster long-term partnerships from the beginning),” he added.